Sarkisian Saro, McIntosh Alyson, Nair Suresh, Shoushtari Alexander N, Callahan Margaret
Hematology and Oncology, Lehigh Valley Cancer Institute, Allentown, USA.
Radiation Oncology, Lehigh Valley Cancer Institute, Allentown, USA.
Cureus. 2020 Oct 29;12(10):e11231. doi: 10.7759/cureus.11231.
The treatment of metastatic melanoma has changed dramatically in the last decade with the introduction of immunotherapy and targeted therapy. A futile disease in the past is now treated with various options, resulting in improvement in progression-free and overall survivals, along with improvement in the quality of life. Having said that, the majority of patients with metastatic melanoma eventually succumb to the disease. Molecular profiling of each tumor in the advanced stage is standard of care now, as this would lead to individualized treatment options for each patient. Here, we present a rare case of fibroblast growth factor receptor 3 (FGFR 3) amplified metastatic melanoma, treated rather unconventionally with FGFR 3 inhibitor erdafitinib.
在过去十年中，随着免疫疗法和靶向疗法的引入，转移性黑色素瘤的治疗发生了巨大变化。过去一种无药可治的疾病现在有了多种治疗选择，这使得无进展生存期和总生存期都得到了改善，生活质量也有所提高。话虽如此，大多数转移性黑色素瘤患者最终还是会死于这种疾病。对晚期每个肿瘤进行分子分析现在已成为标准治疗方法，因为这将为每个患者带来个性化的治疗选择。在此，我们报告一例罕见的成纤维细胞生长因子受体3（FGFR 3）扩增的转移性黑色素瘤病例，该病例采用FGFR 3抑制剂厄达替尼进行了非传统治疗。
